Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Perry

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
British Journal of Clinical Pharmacology|November 8, 2019
A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokineticsDavid L Hava, Lisa Tan, Patrick Johnson, et al.
Journal of Medicinal Chemistry|August 22, 2013
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitisPaul A Roethle, Ryan M McFadden, Hong Yang, et al.
The Journal of Infectious Diseases|August 21, 2023
Alternating Arenavirus Vector Immunization Generates Robust Polyfunctional Genotype Cross-Reactive Hepatitis B Virus-Specific CD8 T-Cell Responses and High Anti-Hepatitis B Surface Antigen TitersSarah Schmidt, Meron Mengistu, Stephane Daffis, et al.
Plos Pathogens|November 21, 2012
Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosidesJamie J Arnold, Suresh D Sharma, Joy Y Feng, et al.
Journal of Medicinal Chemistry|December 11, 2013
Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infectionJohn O Link, James G Taylor, Lianhong Xu, et al.
Journal of Medicinal Chemistry|April 4, 2013
Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patientsAesop Cho, Lijun Zhang, Jie Xu, et al.
Antimicrobial Agents and Chemotherapy|January 15, 2014
Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrugJoy Y Feng, Guofeng Cheng, Jason Perry, et al.
Journal of Medicinal Chemistry|January 27, 2017
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging VirusesDustin Siegel, Hon C Hui, Edward Doerffler, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potentialDavid R Martinez, Fernando R Moreira, Mark R Zweigart, et al.
Journal of Medicinal Chemistry|October 4, 2016
Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I<sub>Na</sub>i), a Phase II Agent with Demonstrated Preclinical Anti-Ischemic and Antiarrhythmic PropertiesJeff A Zablocki, Elfatih Elzein, Xiaofen Li, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
British Journal of Clinical Pharmacology|November 8, 2019
A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokineticsDavid L Hava, Lisa Tan, Patrick Johnson, et al.
Journal of Medicinal Chemistry|August 22, 2013
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitisPaul A Roethle, Ryan M McFadden, Hong Yang, et al.
The Journal of Infectious Diseases|August 21, 2023
Alternating Arenavirus Vector Immunization Generates Robust Polyfunctional Genotype Cross-Reactive Hepatitis B Virus-Specific CD8 T-Cell Responses and High Anti-Hepatitis B Surface Antigen TitersSarah Schmidt, Meron Mengistu, Stephane Daffis, et al.
Plos Pathogens|November 21, 2012
Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosidesJamie J Arnold, Suresh D Sharma, Joy Y Feng, et al.
Journal of Medicinal Chemistry|December 11, 2013
Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infectionJohn O Link, James G Taylor, Lianhong Xu, et al.
Journal of Medicinal Chemistry|April 4, 2013
Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patientsAesop Cho, Lijun Zhang, Jie Xu, et al.
Antimicrobial Agents and Chemotherapy|January 15, 2014
Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrugJoy Y Feng, Guofeng Cheng, Jason Perry, et al.
Journal of Medicinal Chemistry|January 27, 2017
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging VirusesDustin Siegel, Hon C Hui, Edward Doerffler, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potentialDavid R Martinez, Fernando R Moreira, Mark R Zweigart, et al.
Journal of Medicinal Chemistry|October 4, 2016
Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I<sub>Na</sub>i), a Phase II Agent with Demonstrated Preclinical Anti-Ischemic and Antiarrhythmic PropertiesJeff A Zablocki, Elfatih Elzein, Xiaofen Li, et al.
Pageof 4